Statistical methods in musculoskeletal trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
ANCOVA
Multiple imputation / missing data
Cochran-Mantel-Haenszel test
Logistic regression
Odds ratio
Mixed-effects model
Risk difference
MMRM (mixed model for repeated measures)
All musculoskeletal trials
6 results
- contRAst 2Complete statistical analysis of the phase 3 contRAst 2 trial of GSK3196165 (otilimab) versus placebo and tofacitinib in moderately to severely active rheumatoid arthritis.
- CREDO 2Complete statistical analysis of the phase 3 CREDO 2 trial evaluating two olokizumab dosing regimens versus placebo and adalimumab in patients with active rheumatoid arthritis receiving methotrexate.
- DIRECTComplete statistical analysis of DIRECT, a randomized phase 3 trial of denosumab versus placebo in Japanese patients with osteoporosis, including vertebral fracture, non-vertebral fracture, and hip fracture analyses.
- FACT OA1Complete statistical analysis of the phase 3 FACT OA1 trial of fasinumab versus placebo and naproxen for pain from osteoarthritis of the knee or hip, including trial design, WOMAC endpoints, mixed-effects modeling,…
- FACT OA2Complete statistical analysis of FACT OA2, a randomized phase 3 trial evaluating fasinumab versus placebo and NSAIDs for pain from osteoarthritis of the knee or hip, including endpoint definitions, MMRM and Cochran-Mantel-Haenszel…
- RA-MOBILITYComplete statistical analysis of RA-MOBILITY, evaluating sarilumab on top of methotrexate in rheumatoid arthritis, including ACR20 response, HAQ-DI, structural damage, multiplicity, and registry-reported statistical results.